References
- Walter E, Odin P. Cost-effectiveness of continuous subcutaneous Apomorphine in the treatment of Parkinson’s Disease in the UK and Germany. J Med Econ 2015;18:155-65
- National Health Service. The 2014/15 National Tariff. The NHS National Tariff Payment System
- Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson’s disease: a cost‐effectiveness analysis. Neurology 2001;57:663-71
- Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the subthalamic nucleus in Advanced Parkinson's Disease. N Engl J Med 1998;339:1105-11
- Deuschl G, Schade-Brittinger C, Krack P, et al. For the German Parkinson Study Group, Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson’s Disease. New Eng J Med 2006;355:896-908
- Weaver FM, Follet K, Stern M, and the VA CSP #468/NINDS Study Group. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009;301:63-73
- Williams A, Gill S, Jenkinson C, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD Surg trial): a randomised, open‐label trial. Lancet Neurol 2010;9:581-91
- Schuepbach WMM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's Disease with early motor complications. N Engl J Med 2013;368:610-22
- Schüpbach WM, Maltête D, Houeto JL, et al. Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology 2007;68:267-71
- Okun M, Gallo BV, Mandbur G, et al. Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol 2012;11:140-9
- Nujten MJ. The selection of data sources for use in modelling studies. Pharmacoeconomics 1998;13:305-16
- Eddy DM, Hollingworth W, Caro J, et al. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force-4. Value Health 2012;15:843-50
- Eggington S, Valldeoriola F, Chaudhuri KR, et al. The cost‐effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson’s Disease. J Neurol 2014;261:106-16
- Dams J, Siebert U, Bornschein B, et al. Cost-effectiveness of deep brain stimulation in patients with Parkinson's disease. Mov Disord 2013;28:763-71
- Valldeoriola F, Morsi O, Tolosa E, et al. Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease. Mov Disord 2007;22:2183-9
- National Collaboration Centre for Chronic Conditions. Parkinson's Disease. National clinical guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians, 2006
- Valldeoriola F, Puig-Junoy J, Puig-Peiro R. Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study. J Med Econ 2013;16:191-201
- Autiero SW, Eggington S, Valyi A. Cost comparison of deep drain stimulation (DBS) and continued subcutaneous apomorphine infusion (CSAI) in patients with advanced Parkinson’s disease. Value Health 2014;17:A395. http://www.valueinhealthjournal.com/article/S1098‐3015%2814%2902811-3/abstract. Accessed March 23, 2015